Acadra (acadesine) in refractory CLL

[Guest guest]

The results of the Phase I/II study demonstrated that Acadra (acadesine) has an

acceptable safety and tolerability profile in doses which induce reduction in

the leukemic tumour burden.

Acadesine is an AMP-activated protein kinase activator.

The study patient population included 24 patients with relapsed or refractory

CLL who had received a minimum of one prior line of treatment including either a

fludarabine or an alkylator-based regimen.

It is of interest in the treatment of CLL patients who become resistant to

standard therapies and particularly in those who have alterations in the p53

gene

More info and links...http://cllcanada.ca

~chris